Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236368 | 1.00 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4747724 | 0.93 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL14572392 | 0.91 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5620413 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4673103 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL8139161 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5619172 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4747701 | 0.86 | GSK3B (0.49) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4671582 | 0.86 | STAT3 (0.46) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL500723 | 0.86 | GSK3B (0.66) | GSK3BTOP2ATOP2BCACNA1FPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-0990654-B1 | SUBSTITUTED CYCLOBUTYLAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0911328-B1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2006-02-08 | — | — | EP | disclosed |
| US-6121285-A | 5-AMINO-7-(4-(1-AMINOCYCLOPROPYL-3-FLUORO-1-PYRROLIDINYL)-6 -FLUORO-1-(2-FLUORO-1-CYCLOPROPYL)-1,4-DIHYDRO-8-METHOXY-4-OXOQUINOLINE-3 -CARBOXYLIC ACID, FOR EXAMPLE; ANTIMICROBIAL DRUGS WITH HIGH SAFETY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1020459-A1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0990654-A1 | SUBSTITUTED CYCLOBUTYLAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0947513-A1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
| EP-0911328-A1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| EP-0900793-A1 | CYCLOALKYLAMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-03-10 | — | — | EP | disclosed |
| US-5849757-A | Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0816355-A1 | HETEROCYCLIC SPIRO DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | GSK3B 4103/4885TOP2A 138/4885TOP2B 219/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | GSK3B 4399/4885TOP2A 171/4885TOP2B 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.